## One-year all-cause mortality and other clinical outcomes in patients with T2DM and CRC (comparison between matched semaglutide vs other anti-diabetes medication cohorts)

Outcomes	Semaglutide (n = 461)	Other anti-diabetes medications (n = 461		HR (95% CI)
			)	
All-cause mortality	17 (3.7%)	33 (7.2%)	<b>⊢</b>	0.50 (0.28-0.90)
Hospitalization	108 (23.4%)	168 (36.4%)	⊢•	0.56 (0.44-0.71)
ED visits	113 (24.5%)	149 (32.3%)	⊢•	0.69 (0.54-0.88)
ICU admission	18 (3.9%)	31 (6.7%)	<b>⊢</b>	0.56 (0.31-0.99)
Control Outcomes				
Overall medical encounters	457 (99.1%)	450 (97.6%)		1.04 (0.91–1.19)
Outpatient medical encounters	422 (91.5%)	407 (88.3%)	⊦ <del>∳</del> 1	1.00 (0.87–1.15)
			0.10 0.20 0.40 0.70 2.0 3.00 5.00 8.00 Hazard Ratio (HR)	